



ALTERNATE HEALTH ANNOUNCES PRIVATE PLACEMENTS

SAN ANTONIO, TX. August 27, 2018 – Alternate Health Corp. (“**Alternate Health**” or the “**Company**”) (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, wishes to announce that it is undertaking a non-brokered private placement (the “**Private Placement**”) of unsecured convertible notes (the “**Notes**”) under prospectus exemptions available under applicable securities legislation in the aggregate principal amount of up to CAD\$1,700,000 (USD\$1,300,000), maturing and payable on the date that is three years from the date of issuance (the “**Maturity Date**”). The Note shall bear simple interest at a rate of 10% per annum. Interest is payable by the Company on a quarterly basis in arrears. The first interest payment will be September 30, 2018 (or the first business day thereafter) and subsequent interest payment dates during the term will be December 31, March 31 and June 30 (or the first business day thereafter). At the Noteholders’ option, the Notes may be converted into common shares (the “**Shares**”) at a price of CDN \$0.59 per Share (the “**Conversion Price**”), subject to the policies of the Canadian Securities Exchange (the “**Exchange**”). Included in the convertible note placement is a US\$775,000 subscription by Dr. Michael Murphy, Chairman and CEO the Company.

Private Placement of Common Shares

The Company also announces that it is undertaking a non-brokered private placement of up to 6,046,511 common shares at a price of CAD\$0.43 (USD\$0.33) per common share for aggregate gross proceeds of up to CAD\$2,600,000 (USD\$2,000,000). The Company may pay finder’s fees as permitted by applicable securities laws and the policies of the CSE.

“We are extremely pleased to have funds raised to facilitate important expansion opportunities in our product distribution and CBD marketing businesses supported by our blockchain enabled payment software”, says Dr. Murphy, CEO of Alternate Health.

In addition to funding expansion opportunities in product distribution and CBD marketing, private placement proceeds will be used in Alternate Health’s CanaPass and Laboratory businesses and for general working capital purposes. The proposed issuance of Notes to a non-arms’ length party constitutes a related-party transaction under MI 61-101. Because the Company’s shares trade on the Canadian Securities Exchange, the issuance of securities is exempt from the formal valuation requirements of Section 5.4 of MI 61-101 pursuant to Subsection 5.5(b) of MI 61-101 and exempt from the minority approval requirements of Section 5.6 of MI 61-101.

For more information about Alternate Health, visit www.alternatehealth.com.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company’s other verticals. This sophisticated cross-integration of the company’s enterprises has positioned Alternate Health as one of the only cannabis companies that can deliver consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health’s goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to

reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, financing plans and spin off plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.